Taiwan initiated a nationwide pre-end-stage renal disease (ESRD) pay-for-performance (P4P) programme at the end of 2006 to improve quality of care for chronic kidney disease (CKD) patients. This study aimed to examine this programme's effect on patients' clinical outcomes and its cost-effectiveness among advanced CKD patients. Methods: We conducted a longitudinal observational matched cohort study using two nationwide population-based datasets. The major outcomes of interests were incidence of dialysis, allcause mortality, direct medical costs, life years (LYs) and incremental cost-effectiveness ratio comparing matched P4P and non-P4P advanced CKD patients. Competing-risk analysis, general linear regression and bootstrapping statistical methods were used for the analysis. Results: Subdistribution hazard ratio (95% confidence intervals) for advanced CKD patients enrolled in the P4P programme, compared with those who did not enrol, were 0.845 (0.779-0.916) for incidence of dialysis and 0.792 (0.673-0.932) for allcause mortality. LYs for P4P and non-P4P patients who initiated dialysis were 2.83 and 2.74, respectively.
Medicaid Services in the USA implemented the ESRD Quality Incentive Program to incentivize outpatient dialysis facilities to provide high-quality services for patients with ESRD; the P4P programme under the Quality and Outcomes Framework in the UK has included renal indicators to improve care for CKD stages 3-5 patients since 2006 [13, 14] . In Taiwan, a nationwide pre-ESRD P4P programme was launched under NHIA coverage in late 2006.
Before the emergence of P4P initiatives, healthcare providers had been traditionally engaged in improving CKD care through MDC [4, 13, [15] [16] [17] [18] [19] . However, its effectiveness and efficiency in patients with CKD were inconclusive [8, 10, 13, 20] . In addition, most existing studies were based on small sample sizes with short-term follow-up. MDC was associated with lower all-cause mortality, lower risk of dialysis and lower costs in some but not all studies [17, 20, 21] . This may be due in part to the significant variation in the composition of the MDC team, poor provider adherence to practice guidelines or lack of financial incentives to provide MDC on a long-term basis [8, 10, 21, 22] . In response to these concerns, P4P, which rewards providers for delivering high-quality care, is widely discussed as a strategy to address these deficiencies [8, 10, 11] . To date, little is known about the use of P4P schemes to stimulate delivery of pre-ESRD care through national health policy, or about whether such schemes actually affect long-term healthcare quality, the cost-effective use of resources and cost savings for patients with CKD at population level.
This study aimed to investigate whether the nationwide pre-ESRD P4P programme in Taiwan affected the risks of all-cause mortality and dialysis initiation, and whether the programme allowed for the cost-effective use of resources among advanced CKD patients from a single-payer perspective. We used a population-based cohort study design to evaluate the long-term effect of the pre-ESRD P4P programme on enrolled P4P patients compared with a control group of patients not participating in the P4P programme.
M A T E R I A L S A N D M E T H O D S
Brief overview of Taiwan's pre-ESRD P4P programme Taiwan has high ESRD incidence and prevalence rates and bears a substantial economic burden from this disease [2] . In an effort to improve quality of care for CKD patients before ESRD develops, the NHIA initiated a pre-ESRD P4P programme at the end of 2006. The primary goals of this programme are to provide adequate care for CKD stages 3b, 4 and 5 patients, slow the deterioration of renal function, reduce incidence of ESRD and provide early preparation for dialysis initiation [23] . This programme comprises several important features. First, an eligible MDC team (which must consist of at least one nephrologist as well as well-trained renal nurses and dieticians) enrolled patients voluntarily into this special P4P programme for pre-ESRD care. Second, the teams were required to follow clinical guidelines established for CKD patients at different stages. Third, provision of follow-up care every 3 months included medical history assessment, physical examination, laboratory evaluation, management plan evaluation and dietary education.
Fourth, the participating teams received an extra NT$1200 (US$40) per initial enrolment visit, NT$600 (US$20) per follow-up visit and NT$600 (US$20) per annual evaluation visit. All eligible MDC teams were mandated to submit follow-up reports and claims data to the NHIA for reimbursement.
Data source
We used data from four population-based database sources in Taiwan from 2007 to 2012. The first was a nationwide pre-ESRD P4P database, from which we precisely identified patients enrolled in the P4P programme. The second was the NHIA claims database, from which we obtained information on comorbid conditions and health provider characteristics. The third was a registry of catastrophic illnesses, from which we identified long-term dialysis patients and the date on which dialysis began. The fourth contained death registry data, from which we obtained accurate date of death information. This study was approved by the Institutional Review Board at Kaohsiung Medical University Hospital.
Study population
Using nationwide NHIA claims data, we first included pre-ESRD patients with the first three primary diagnosis codes [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 585 or 581.9 given the pre-ESRD P4P programme policies] for at least one outpatient visit or inpatient admission and followed by a nephrologist between 1 January 2007 and 31 December 2009. To further ensure that patients were regularly treated for CKD, eligible patients were required to have had at least two outpatient visits with these codes within 1 year after the first date of diagnosis. Using the P4P database, we then identified newly enrolled P4P patients for the P4P cohorts during the patient identification period and defined the index date as the date of first enrolment. We then identified non-P4P patients for the comparison groups who were not found to be enrolled in the P4P programme during the above-stated time period. Given that non-P4P patients lack specific enrolment index dates, we randomly assigned index dates based on the dynamic frequency distribution of time exposure to the P4P intervention from the P4P group [24] . We excluded patients whose insurance file was incomplete (e.g. lack of sex or birthdate information). Finally, we followed previous studies in identifying P4P and non-P4P advanced CKD patients who had received erythropoiesis-stimulating agent (ESA) treatment within 2 years, 1 year prior and post, of the index date [25] [26] [27] . According to the NHIA reimbursement policy regulations, regardless of participation in the pre-ESRD P4P programme, an ESA can be distributed and reimbursed only for advanced CKD patients whose serum creatinine is >6 mg/dL (approximately equivalent to an estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m 2 ) and whose haematocrit is <28%, to maintain a haematocrit level not to exceed 36%. A total of 2093 P4P and 2161 non-P4P advanced CKD (stage 5) patients with anaemia were included in the final analysis. Figure 1 provides more information about study inclusion and exclusion criteria.
To avoid potential selection bias and confounding factors, we used a propensity score matching (PSM) approach to determine adequate comparison groups. Using a logistic regression
model, we created propensity scores that predicted the probability of enrolment into the pre-ESRD P4P programme. The PSM calliper matching method with a 1-to-1 match was used to match intervention group members with comparison group members based on their propensity scores [28] . This approach aimed to find the nearest distance of probabilities regarding the estimated propensity scores to determine the best matches with the smallest standard deviations between case and control groups. If more than one potential control group member had the same propensity score as a case member, the algorithm randomly selected one for inclusion in the control group [28] . The covariates included patient demographic characteristics (age, sex, income status and urban/rural residence), pre-ESRDrelated comorbid conditions (diabetes, hypertension, myocardial infarction, congestive heart failure, peripheral vascular disease, stroke and gout) and comorbid conditions based on the Charlson comorbidity index (CCI), which measures overall clinical condition by weighting comorbid conditions. This index has been widely used by health researchers to measure the burden and severity of a disease; lower scores represent lower risk [29, 30] . In addition, because the P4P programme required health staff to work as a team and cost structures may differ in different health institutions, healthcare provider characteristics were included to identify the resources and capacities of individual healthcare institutions. Characteristics included accreditation level (medical centre, regional hospital, local hospital or clinic), teaching status and geographic location (Taipei, northern, central, southern, Kao-Ping or eastern area). 
Outcomes of interest
Effectiveness and cost measures were examined in the matched P4P and non-P4P-advanced CKD patients. ESRD warranting RRT initiation and mortality due to any cause were the primary end-points. Incident dialysis patients were identified by examining ICD-9-CM codes 585 in the Registry of Catastrophic Illness and obtaining the event date of first dialysis treatment during the follow-up period. Initial dialysis modality [haemodialysis (HD) or peritoneal dialysis (PD)] was also identified. To compare groups, we followed each P4P and non-P4P patient until the study end date on 31 December 2012. Each patient was followed up for 3 years. Patients who dropped out of the insurance programme or died were censored. We calculated total person-years for each patient, dialysis incidence rates and all-cause mortality rates per 1000 person-years. Life years (LYs) were also measured from the index date until death or the date of last follow-up within 3 years in the censored data.
We analysed medical costs from a single-payer perspective. We analysed costs over the 3-year period for each patient and discounted the effects over the expected patient life. CKDrelated medical costs (with ICD-9-CM diagnosis codes 580-589) for outpatient visits, emergency department visits, hospital admissions and dialysis outpatient visits (with specific treatment or medication billing codes for HD or PD in the NHIA claims), and other-cause medical costs for outpatient visits, emergency department visits and hospital admissions were measured. We measured costs separately for patients who progressed to ESRD and underwent dialysis and for those who did not during the follow-up period because health utilization and costs differed for these two groups. Cost data were extracted from the NHIA claims and adjusted to 2007 prices based on the NHI global budgeting annual negotiation rate ($3% discount rate). Costs are presented in New Taiwan Dollars (NT$). The exchange rate between NT$ and US$ was $30:1 in this study.
Economic and statistical analytical approach
Competing-risk regression models based on cause-specific and subdistribution hazards were used to analyse the association between the effect of the pre-ESRD P4P program and two primary effectiveness end-points (incidence of RRT initiation and all-cause mortality), while controlling for patient demographic and clinical characteristics and healthcare organization characteristics.
In addition, we conducted a cost-effectiveness analysis. Multiple generalized linear regressions were used to examine the increments of effectiveness (LYs) and costs between P4P and non-P4P patients while controlling for the confounders listed in Table 1 . A heteroskedasticity-robust standard error adjustment was used, and patients were clustered within healthcare institutions to control for unequal error variances across institutions. We then calculated incremental costs and effectiveness by differences in these values for P4P and non-P4P patients using adjusted predicted estimates. In addition, we calculated the incremental cost-effectiveness ratio (ICER) as the ratio of the difference in costs and divided by the difference in effectiveness between groups [31, 32] . All incremental measures were adjusted for patient demographic and clinical characteristics Only for patients who underwent dialysis after enrolment into the P4P programme.
and healthcare institution characteristics. Bootstrapping with 500 replications with a sample size equivalent to the original was used to obtain standard errors and confidence intervals for incremental measures [33, 34] . All statistical operations were performed using SAS version 9.3 (SAS institute, Cary, NC, USA) and Stata SE 13 version. A P-value of <0.05 was considered significant. Table 1 summarizes baseline patient and healthcare provider characteristics for the P4P and non-P4P-advanced CKD patients (pre-and post-matching). After matching, we included 1473 paired P4P and non-P4P patients. Significant differences in some variables (age, CCI and health care organization were found between the pre-matched intervention and comparison groups (P < 0.001) with respect to all characteristics assessed. However, after PSM 1-to-1 matching, the two groups were found to be similar. Table 2 compares the numbers of total person-years within 3-year follow-up, incidence of RRT, and all-cause mortality rates per 1000 person-years and selections of dialysis modalities between P4P and non-P4P patients. The incidence rate ratio between cohorts was 0.84 (P < 0.001) for RRT initiation and 0.80 (P ¼ 0.003) for all-cause mortality. Most patients who progressed to ESRD after enrolling into the program selected HD (P ¼ 0.011). Table 3 presents results from competing-risk regression models for the incidence of dialysis and all-cause mortality comparing P4P with non-P4P advanced CKD patients. Overall, our results indicated that P4P patients had a lower risk of dialysis initiation and mortality than non-P4P patients. Specifically, the subdistribution hazard ratio (SHR) (95% confidence intervals) was 0.845 (0.779-0.916) for incidence of dialysis and 0.792 (0.673-0.932) for all-cause mortality. As for other confounding factors, older patients (ages 66-75 years, !76 years) had higher rates of death and lower rates of dialysis initiation than younger patients (age <45 years). Patients with more severe comorbidity also had a higher risk of death and dialysis initiation. Figure 2 presents adjusted cumulative hazard curves for risks of death and dialysis initiation comparing P4P and non-P4P patients. Table 4 reports the incremental cost-effectiveness estimates and ICERs by direct medical costs and LYs for P4P and non-P4P patients with or without dialysis initiation separately. Results indicated that P4P groups received significantly more effective care (LY gains) than their corresponding non-P4P groups, and that their cost savings were significantly greater. Specifically, with regard to effectiveness of care, LYs were 2.83 and 2.74 for P4P and non-P4P patients who initiated dialysis, respectively, and 2.63 and 2.46 for P4P and non-P4P who did not initiate dialysis, respectively. Adjusted incremental values per LYs gained were 0.08 (P < 0.001) and 0.16 (P < 0.001), respectively. With regard to incremental direct medical costs between P4P and non-P4P patients, the difference in adjusted incremental CKD-related costs and other-cause-related costs were NT$114 704 (US$3823) and NT$32 420 (US$1080) for patients who initiated dialysis, respectively, and NT$3434 (US$114) and NT$45 836 (US$1572) for patients who did not initiate dialysis, respectively, during the 3-year follow-up period. Overall, compared with those for non-P4P patients, ICER medical costs by gains in LYs were significantly greater for P4P patients in both groups (all P < 0.001). Specifically, the ICER of total CKD-related costs for P4P patients who initiated dialysis was NT$1 547 067 (US$51 568) and the ICER of total othercause costs was NT$423 122 (US$$14 104) per LY gained; the ICER of total CKD-related costs for P4P patients who did not initiate dialysis was NT$16 231 (US$541) and the ICER of total other-cause costs was NT$404 979 (US$13 499) per LY gained.
R E S U L T S

D I S C U S S I O N
Although the P4P has been used to improve healthcare delivery and quality of care for patients with chronic illness, evidence of its effect on delaying ESRD progression, improving survival and reducing medical costs in a cost-effective manner for advanced CKD patients remained limited [12, 13, 32, 35, 36] . We included advanced CKD patients who did and did not enrol in the programme from 2007 to 2009, using large nationwide populationbased data to evaluate whether a pre-ESRD P4P programme effectively decreased the risk of dialysis initiation and all-cause mortality during 3-year follow-up. Our findings indicate that advanced CKD patients enrolled in a pre-ESRD P4P programme had lower risks of progressing to ESRD and of mortality, and the time to dialysis therapy was significantly longer (430 versus 347 days) (P < 0.001).
The superior outcomes for the P4P advanced CKD patients might be explained by several reasons regarding specific aspects FIGURE 2: Adjusted cumulative incidence curve for risks of death and dialysis initiation between P4P and non-P4P patient-advanced CKD cohorts. CI, confidence interval. 
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Incremental value here presented the value of P4P À non-P4P.
Bootstrapped 95% confidence interval (CI) was obtained from predicted difference values from the multiple generalized linear regression models.
100 times replications with sample size equivalent to the original. Covariates that were controlled were listed in the of the P4P programmes. First, the pre-ESRD P4P programme in Taiwan requires participating healthcare providers to adhere to the guidelines of the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-K/DOQI) for standard care of patients with CKD regardless of disease severity. The K/ DOQI guidelines make recommendations for the evaluation, monitoring and management of patients with CKD [37] [38] [39] [40] . Based on guideline recommendations, participating nephrologists and their teams must continuously monitor process outcome indicators depending on CKD stage to receive quality rewards. For example, for advanced CKD stage 5 patients, several key quality indicators were monitored: percentage using erythropoietin; percentage with haematocrit >28%; percentages with blood pressure <130/80 mmHg, total cholesterol and triglycerides <200 mg/dL and HbA1c <7.5%; and percentage with vascular access preparation before dialysis initiation. Second, the reduced risks of progression to ESRD or mortality may be explained in part by the multidisciplinary team approach in the pre-ESRD P4P programme. The team includes physicians, nurses, case managers, pharmacists and nutritionists. A coordinating team developed a system of immediate integrated care services for CKD patients during routine office visits. Previous studies have supported the improvement that multidisciplinary team approaches show regarding quality outcomes for CKD patients [17] [18] [19] [20] [41] [42] [43] . Third, P4P-enrolled advanced CKD patients had frequent nephrology visits, once every 3 months. A previous study suggested that CKD patients who received consistent care due to required nephrology visits at least once every 3 months in the 6 months preceding RRT initiation had a superior prognosis [44] . With respect to other risk factors, holding all other things constant, this study found that the incidence of death and dialysis initiation had inverse relationships depending on patient age. Most older patients were more likely to die than to develop ESRD and initiate dialysis; conversely, younger patients were more likely to develop ESRD than to die. These results are consistent with a study by O'Hare et al. showing that age is an important effect modifier in CKD [45] .
In addition to effectiveness outcomes, we evaluated the costeffectiveness of the pre-ESRD P4P programme for enrolled patients compared with a control group of patients not participating in the P4P programme [20, 23, 42, 46] . The field of economic analysis of P4P programmes in CKD care is still in its infancy [6, 7, 12, 35, 36, 47, 48] . Several studies have reported on the cost-saving effect of MDC; however, few studies have addressed the financial benefits of a nationwide P4P programme for CKD patients. Rather than relying on simulation modelling of the schemes' consequences, we directly estimated the incremental effects of costs and cost-effectiveness separately for patients who progressed to ESRD and initiated dialysis and those who did not during the follow-up period [6, 7, 35, 36] . For both the case and control cohorts, we observed that the P4P significantly increased adjusted LYs and allowed for the costeffective use of resources, particularly for patients who initiated dialysis. Similar results were found by Hopkins et al. [47] , who examined the cost-effectiveness of a multifaceted pre-ESRD care model for CKD stages 3 and 4 patients in a randomized clinical trial in Canada, and suggested that cutoff levels for eGFR <40 or 45 mL/min/1.73 m 2 were more cost-effective than for above that cutoff.
Furthermore, our study found lower CKD-related inpatient hospitalization costs but higher outpatient costs for P4P patients who did not progress to ESRD, and lower CKD-related costs (outpatient, hospitalization and dialysis costs) for P4P patients who initiated dialysis. These results were also consistent with previous studies [23, 42, 46] . For example, two studies found that MDC patients have significantly more frequent visits, higher medical costs for outpatient care and fewer hospitalizations before dialysis initiation [20, 23] . Additionally, because of better preparation for RRT, previous studies also found that MDC patients had less unplanned urgent dialysis, fewer hospital days, and lower incidence of cardiovascular events at dialysis initiation or in the post-dialysis period [20, 23, 42, 46] .
Our study has several limitations. First, given the limitation of our study data periods, we were not able to track the number of years since CKD was diagnosed or to identify whether patients were newly diagnosed. Second, some unobservable confounders for individual patients (e.g. life style, prescription adherence, illness experience, smoking status, continuity of care or baseline eGFR value) were not available. Although these baseline confounding factors were not part of the study design, and all characteristics related to health outcomes in the P4P programme were covered by the measured variables among P4P and non-P4P patients, caution is necessary when interpreting the effect of the P4P programme on health outcomes. Third, over-and underdiagnosis may occur because the complications of interest were defined using ICD-9-CM codes in administrative claims. Fourth, given the lack of eGFR values to identity CKD stages in the administrative claims data, we followed previous studies in identifying advanced CKD patients as those who received ESA treatments, given the NHI reimbursement policy requiring that CKD patients with serum creatinine >6 mg/dL (approximately equivalent to eGFR <15 mL/min/1.73 m 2 ) and haematocrit <28% receive ESA treatment to maintain a haematocrit level not to exceed 36% [25] [26] [27] . In other words, our selected study subjects were advanced CKD (stage 5) patients with anaemia. Our study results may not be applicable to patients with less severe CKD, such as those with CKD stage 3b or 4. Fifth, we only estimated direct medical costs paid by the NHIA rather than, as Meacock et al. suggested [36] , including opportunity costs, indirect costs or NHIA infrastructure/ administrative costs. Finally, the data we used were obtained from CKD populations in Taiwan, so the results may not generalize to other P4P programmes in other countries.
C O N C L U S I O N
In conclusion, compared with advanced CKD patients who did not enrol in the P4P programme, P4P patients had lower risks of incidence of dialysis initiation and of death. In addition, our empirical findings suggest that the pre-ESRD P4P programme in Taiwan provided long-term cost-effective use of resources and cost savings for advanced CKD patients.
